Compassionate Use for Subcutaneous (SC) Belimumab

You may be eligible if

• This is a protocol to support an emergency IND for compassionate use in one patient requiring use of belimumab subcutaneous for SLE treatment (lacks venous access and cannot receive IV belimumab).
• Eligibility criteria is based on the following, as provided within GSK's policy on compassionate use:
• The illness being treated is life threatening or seriously debilitating.
• There are no satisfactory alternative treatments (confirmed by the HCP).
• There is sufficient evidence to believe the benefit to the patient justifies the risk You can access GSK's Policy on Compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.